Hims & Hers Shares Surge 40% After Novo Nordisk Partnership Enables Ozempic, Wegovy Sales on Platform

Hims & Hers (HIMS) posted a 40% gain in premarket trading on March 9, 2026, after announcing a definitive agreement with Novo Nordisk to distribute the company’s flagship GLP-1 drugs, Ozempic and Wegovy, via its proprietary telehealth platform. The partnership marks the resolution of a months-long disagreement that had restricted Hims & Hers’ ability to offer these high-demand medications, which are central to the growing weight management and metabolic health market. The agreement enables Hims & Hers to directly onboard patients seeking weight-loss and type 2 diabetes treatments through its digital care model, integrating prescription access with medical consultations and ongoing monitoring. This move significantly enhances the company’s monetization potential, as Ozempic and Wegovy each generated over $11 billion in global sales for Novo Nordisk in 2025. The inclusion of these drugs on Hims & Hers' platform is expected to drive user acquisition and increase average revenue per user (ARPU) by at least 35% in the second half of 2026. The stock surge reflects investor confidence in Hims & Hers’ expanded commercial reach and strategic positioning in the digital therapeutics space. The partnership also strengthens the company’s competitive edge against rivals like Teladoc Health and Ro Health, which are expanding their prescription services amid rising demand for accessible metabolic care. The broader healthcare technology sector, as measured by the Health Care Select Sector SPDR Fund (XLV), also saw a modest uptick, while the CBOE Volatility Index (VIX) dipped 2.3% to 14.2, signaling reduced market uncertainty. The development underscores the growing convergence of pharmaceutical innovation and digital health delivery systems, with Hims & Hers now serving as a critical distribution channel for premium prescription therapies. The company is expected to report first-quarter 2026 results with a projected 48% year-over-year increase in total revenue, driven largely by the new partnership.